Arena Pharmaceuticals Revenue and Competitors

Location

$390.7M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Arena Pharmaceuticals's estimated annual revenue is currently $37k per year.(i)
  • Arena Pharmaceuticals received $405.7M in venture funding in March 2018.
  • Arena Pharmaceuticals's estimated revenue per employee is $176
  • Arena Pharmaceuticals's total funding is $390.7M.
  • Arena Pharmaceuticals's current valuation is $5.7B. (January 2022)

Employee Data

  • Arena Pharmaceuticals has 210 Employees.(i)
  • Arena Pharmaceuticals grew their employee count by -33% last year.

Arena Pharmaceuticals's People

NameTitleEmail/Phone
1
VP - Global Commercial Marketing and PlanningReveal Email/Phone
2
VP, Global Marketing and PlanningReveal Email/Phone
3
Director, Clinical OperationsReveal Email/Phone
4
Senior Director, Nonclinical Development and Clinical PharmacologyReveal Email/Phone
5
Director, Clinical OperationsReveal Email/Phone
6
Associate Director, Study Recruitment OptimizationReveal Email/Phone
7
Deputy Director CommerceReveal Email/Phone
8
Senior Director, Atopic Dermatitis Program Lead, Clinical DevelopmentReveal Email/Phone
9
Quality Assurance ManagerReveal Email/Phone
10
Manager GD Training QualityReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$102.7M51125%N/AN/A
#2
$0.4M20%N/AN/A
#3
$38.6M1923%N/AN/A
#4
$35M1272%$62.5MN/A
#5
$36.6M18218%N/AN/A
#6
$131.9M656-3%N/AN/A
#7
$133.5M664N/AN/AN/A
#8
$72.8M362-4%N/AN/A
#9
$551.9M1716-2%N/AN/A
#10
$11.7M5812%N/AN/A
Add Company

What Is Arena Pharmaceuticals?

We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Arena is headquartered in San Diego, CA, with international operations in Zug, Switzerland.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$390.7M

Total Funding

210

Number of Employees

$37k

Revenue (est)

-33%

Employee Growth %

$5.7B

Valuation

N/A

Accelerator

Arena Pharmaceuticals News

2022-04-19 - Movers & Shakers: John Maraganore, Larry Alstiel, Brad ...

Ocuphire Pharma, Inc.: Jay Pepose was appointed chief medical ... after more than four years at Arena Pharmaceuticals where he served as VP...

2022-03-30 - Will Pfizer Stock See Higher Levels After A 10% Rise In A Month?

... Pfizer's acquisition of Arena Pharmaceuticals for $6.7 billion. This is largely seen as a positive for Pfizer, given Arena's robust drug...

2022-03-22 - How Pfizer's $6.7 Billion Arena Pharmaceuticals Buyout Could ...

Pfizer recently completed a $6.7 billion acquisition of Arena Pharmaceuticals. Pfizer bought Arena Pharmaceuticals to access Etrasimod, an...

2020-11-10 - Arena Pharmaceuticals : Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of moderate-to ...

2020-11-10 - ARENA PHARMACEUTICALS, INC. Arena Pharmaceuticals : Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial

SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of moderate-to ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$33.5M21026%N/A
#2
$15M2108%N/A
#3
$33.5M2103%N/A
#4
$15M21014%N/A
#5
$7.5M211-9%N/A

Arena Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2009-03-24$50.0MUndisclosedAzimuth Opportunity LtdArticle
2009-06-18$100.0MUndisclosedPiper Jaffray and CoArticle
2010-06-04$35.5MUndisclosedDeerfield ManagementArticle
2011-03-30$35.5MUndisclosedArticle
2012-01-12$33.0MReplaces: DArticle
2012-05-17$UndisclosedUndisclosedJefferies & Company Inc, Piper Jaffray & CoArticle
2015-01-22$UndisclosedUndisclosedJefferies LLCArticle
2017-04-18$79.4MUndisclosedCitigroupArticle
2017-07-12$150.0MUndisclosedCitigroup, Leerink PartnersArticle
2018-03-22$405.7MUndisclosedMultipleArticle